Loading…
We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Head-to-head evidence comparison — which supplement is right for you?
Citicoline vs Omega-3: Omega-3 has the stronger overall evidence (9 vs 6/10); they're alternatives for support mood — the best pick depends on your goals. Take the 60-second quiz for a pick tailored to your goals.
Omega-3 wins 2 of 3 categories. Both are solid choices — the best pick depends on your specific goals.
Verdict
Probably helps
3 of 5 studies with measurable effects showed benefit.
Top outcomes
Verdict
Probably helps
10 of 15 studies with measurable effects showed benefit.
Top outcomes
Shared outcomes (2)
Outcomes where both Citicoline and Omega-3 have evidence — compare verdict strength side-by-side.
250-500mg daily
Morning for daytime cognitive enhancement
Cognizin® branded citicoline
2-3g combined EPA+DHA daily (a typical label dose, not the dose used in the cited trials, which gave 1 g or 3.25 g of omega-3 a day, or 1 to 4 g of fish oil a day without stating its EPA+DHA content)
With meals containing fat
Triglyceride form fish oil
1-4 weeks
4-8 weeks
1-2 weeks
4-8 weeks
2-4 weeks
Immediate
4-12 weeks
Is Citicoline Effective in Preventing and Slowing Down Dementia?-A Systematic Review and a Meta-Analysis
Nutrients (2023) · Meta analysis
Systematic review of 7 studies published 2010 to 2022 in people with mild cognitive impairment, Alzheimer's disease or post-stroke dementia, 6 of them pooled in a meta-analysis.
Application of Citicoline in Neurological Disorders: A Systematic Review
Nutrients (2020) · Systematic review
In an animal model of nerve damage and neuropathy, citicoline stimulated regeneration and lessened pain.
Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly
Cochrane Database of Systematic Reviews (2005) · Systematic review
Positive effects on memory
Marine n-3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer
The New England journal of medicine (2019) · Rct · n=25871
During a median follow-up of 5.3 years, a major cardiovascular event occurred in 386 participants in the n-3 group and in 419 in the placebo group (hazard ratio, 0.92; 95% confidence interval [CI], 0.80 to 1.06; P=0.24).
Omega-3 fatty acids for intermittent claudication
The Cochrane database of systematic reviews (2024) · Meta analysis · n=1830
Omega-3 compared with a control may have little to no effect on ankle-brachial index (MD -0.02, 95% CI -0.08 to 0.04; 3 studies, 168 participants; very low-certainty evidence).
A systematic review and meta-analysis of the omega-3 fatty acids effects on brain-derived neurotrophic factor (BDNF)
Nutritional neuroscience (2024) · Meta analysis · n=587
12 RCTs with 587 subjects: omega-3 supplementation increased serum BDNF versus placebo (SMD 0.72, 95% CI 0.28 to 1.15), with high heterogeneity (I2 = 84.39%).
At 500 mg a day for 12 weeks, a randomised placebo-controlled trial in 100 healthy older adults with age-associated memory impairment found greater gains in episodic and composite memory (PMID 33978188). A 4-week controlled trial in 24 older adults with memory deficits gave 500 or 1,000 mg a day and found similar free-recall gains in both groups, so the curve is flat from 500 to 1,000 mg (PMID 9203170). At 1 g a day for 12 months, an open-label randomised trial in 347 people after a first ischaemic stroke found better attention-executive function and temporal orientation than usual care (PMID 23406981). The 2,000 mg ceiling is a 12-week placebo-controlled trial in 62 adults with alcohol use disorder, where citicoline titrated to 2,000 mg a day was well tolerated but did not change cognitive measures (PMID 30457668). The dementia meta-analysis (PMID 36678257) found improved cognitive status in studies of poor quality and gives no doses. No trial found a better dose than 500 mg, so no optimal dose is set.
The points are the dose bands of a meta-analysis of 10 randomised trials with 1,426 adults (PMID 37028202): EPA-rich products at 1 to under 2 g of EPA a day reduced depression severity (SMD -0.43), while 2 g a day or more did not (SMD -0.20, not significant), so the 2 g point is plotted as no effect. Doses are grams of EPA, not EPA plus DHA. The Cochrane review of 33 placebo-controlled trials found a small to modest effect, unlikely to be clinically meaningful and rated very low certainty, with no difference in remission or response (PMID 34817851). No trial compared doses directly.
AI-estimated from published studies. Interpret as directional guidance.
Omega-3 has a higher evidence score (9/10 vs 6/10) and wins in 2 of 3 categories.
For support mood, Omega-3 has a higher relevance score (88 vs 50).
No documented interaction was found in the data searched. This does not establish that this exact combination is safe.
Caffeine+L-theanine works; bacopa needs weeks; most "brain pills" are hype. The honest tier list.
The honest tier list — proven staples vs situational vs mostly marketing. The hub the other guides feed into.
On Ozempic/Wegovy/Mounjaro? What actually helps — muscle preservation, GI relief, nutrient gaps (no upsell).
Which supplements clash with blood thinners, thyroid meds, antibiotics & more — and what to do.
The right pick depends on your goals. Answer a few quick questions for a personalised recommendation — or dig into the full evidence on each.